These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34623418)

  • 21. Smoking Cessation and Changes in Anxiety and Depression in Adults With and Without Psychiatric Disorders.
    Wu AD; Gao M; Aveyard P; Taylor G
    JAMA Netw Open; 2023 May; 6(5):e2316111. PubMed ID: 37256615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of scores from a telephone administered multiple sclerosis walking scale-12 in persons with multiple sclerosis.
    Motl RW; Plummer P; Backus D; Hebert JR; Neal WN; Ng A; Lowman J; Bethoux F; Schmidt H; McBurney R; McCully KK; Cutter G
    Mult Scler Relat Disord; 2024 Jun; 88():105715. PubMed ID: 38889558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges for dedicated smoking cessation services in developing countries.
    Tadzimirwa GY; Day C; Esmail A; Cooper C; Kamkuemah M; Dheda K; Van Zyl-Smit RN
    S Afr Med J; 2019 May; 109(6):431-436. PubMed ID: 31266563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study.
    Tanasescu R; Constantinescu CS; Tench CR; Manouchehrinia A
    Nicotine Tob Res; 2018 Apr; 20(5):589-595. PubMed ID: 28402456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Smoking cessation for people with severe mental illness (SCIMITAR+): a pragmatic randomised controlled trial.
    Gilbody S; Peckham E; Bailey D; Arundel C; Heron P; Crosland S; Fairhurst C; Hewitt C; Li J; Parrott S; Bradshaw T; Horspool M; Hughes E; Hughes T; Ker S; Leahy M; McCloud T; Osborn D; Reilly J; Steare T; Ballantyne E; Bidwell P; Bonner S; Brennan D; Callen T; Carey A; Colbeck C; Coton D; Donaldson E; Evans K; Herlihy H; Khan W; Nyathi L; Nyamadzawo E; Oldknow H; Phiri P; Rathod S; Rea J; Romain-Hooper CB; Smith K; Stribling A; Vickers C
    Lancet Psychiatry; 2019 May; 6(5):379-390. PubMed ID: 30975539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychometric properties of the Croatian version of the depression, anxiety, and stress scale-21 and multiple sclerosis impact scale-29 in multiple sclerosis patients.
    Rogić Vidaković M; Šimić N; Poljičanin A; Nikolić Ivanišević M; Ana J; Đogaš Z
    Mult Scler Relat Disord; 2021 May; 50():102850. PubMed ID: 33636617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression.
    Wu J; Olsson T; Hillert J; Alfredsson L; Hedström AK
    J Neurol Neurosurg Psychiatry; 2023 Aug; 94(8):589-596. PubMed ID: 37001984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Smoking Cessation With Subsequent Risk of Cardiovascular Disease.
    Duncan MS; Freiberg MS; Greevy RA; Kundu S; Vasan RS; Tindle HA
    JAMA; 2019 Aug; 322(7):642-650. PubMed ID: 31429895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychometric Properties of the HADS Measure of Anxiety and Depression Among Multiple Sclerosis Patients in Croatia.
    Jerković A; Proroković A; Matijaca M; Vuko J; Poljičanin A; Mastelić A; Ćurković Katić A; Košta V; Kustura L; Dolić K; Ðogaš Z; Rogić Vidaković M
    Front Psychol; 2021; 12():794353. PubMed ID: 34917005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales.
    Sonder JM; Balk LJ; Bosma LV; Polman CH; Uitdehaag BM
    Mult Scler; 2014 Oct; 20(12):1616-23. PubMed ID: 24710798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of prolonged-release fampridine
    Hupperts R; Gasperini C; Lycke J; Ziemssen T; Feys P; Xiao S; Acosta C; Koster T; Hobart J
    Ther Adv Neurol Disord; 2022; 15():17562864221090398. PubMed ID: 35601756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depressive Symptoms Are Associated With More Negative Functional Outcomes Than Anxiety Symptoms in Persons With Multiple Sclerosis.
    Gill S; Santo J; Blair M; Morrow SA
    J Neuropsychiatry Clin Neurosci; 2019; 31(1):37-42. PubMed ID: 30187820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breaking the cycle of smoking and pain: do pain-related anxiety and pain reduction expectancies sabotage attempts to quit smoking and can smoking cessation improve pain and pain-related disability outcomes?
    Parkerson HA; Sareen J; Asmundson GJG
    Cogn Behav Ther; 2021 Mar; 50(2):154-171. PubMed ID: 32852241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales.
    Sonder JM; Bosma LV; van der Linden FA; Knol DL; Polman CH; Uitdehaag BM
    Mult Scler; 2012 Feb; 18(2):196-201. PubMed ID: 21908479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A bespoke smoking cessation service compared with treatment as usual for people with severe mental ill health: the SCIMITAR+ RCT.
    Peckham E; Arundel C; Bailey D; Crosland S; Fairhurst C; Heron P; Hewitt C; Li J; Parrott S; Bradshaw T; Horspool M; Hughes E; Hughes T; Ker S; Leahy M; McCloud T; Osborn D; Reilly J; Steare T; Ballantyne E; Bidwell P; Bonner S; Brennan D; Callen T; Carey A; Colbeck C; Coton D; Donaldson E; Evans K; Herlihy H; Khan W; Nyathi L; Nyamadzawo E; Oldknow H; Phiri P; Rathod S; Rea J; Romain-Hooper CB; Smith K; Stribling A; Vickers C; Gilbody S
    Health Technol Assess; 2019 Sep; 23(50):1-116. PubMed ID: 31549622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial.
    Anthenelli RM; Gaffney M; Benowitz NL; West R; McRae T; Russ C; Lawrence D; St Aubin L; Krishen A; Evins AE
    J Gen Intern Med; 2019 Jun; 34(6):862-870. PubMed ID: 30847828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anxiety and depression in multiple sclerosis patients around diagnosis.
    Giordano A; Granella F; Lugaresi A; Martinelli V; Trojano M; Confalonieri P; Radice D; Solari A;
    J Neurol Sci; 2011 Aug; 307(1-2):86-91. PubMed ID: 21621796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smoking and disease progression in multiple sclerosis.
    Healy BC; Ali EN; Guttmann CR; Chitnis T; Glanz BI; Buckle G; Houtchens M; Stazzone L; Moodie J; Berger AM; Duan Y; Bakshi R; Khoury S; Weiner H; Ascherio A
    Arch Neurol; 2009 Jul; 66(7):858-64. PubMed ID: 19597087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoking characteristics and years since quitting smoking of US adults diagnosed with lung and bladder cancer: A national health and nutrition examination survey analysis.
    Beatrici E; Labban M; Filipas DK; Stone BV; Reis LO; Dagnino F; Lughezzani G; Buffi NM; Lipsitz SR; Clinton TN; Matulewicz RS; Trinh QD; Cole AP
    Int Braz J Urol; 2024; 50(2):199-208. PubMed ID: 38386790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-Response Association of Low-Intensity and Nondaily Smoking With Mortality in the United States.
    Inoue-Choi M; Christensen CH; Rostron BL; Cosgrove CM; Reyes-Guzman C; Apelberg B; Freedman ND
    JAMA Netw Open; 2020 Jun; 3(6):e206436. PubMed ID: 32492162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.